NEWS

New research results and forthcoming trials were presented at ESMO 2025, underlining EORTC’s commitment to patient-centred research.

Sessions and presentations covered a wide range of themes including:

1. What happens when patients stop treatment during trials?
2. Better ways of involving patients in research
3. Understanding long-term survival in glioblastoma
4. Two new trials will study individualised treatments in genitourinary cancers
5. Searching for new treatments for adult fibrosarcoma patients
6. Better ways of measuring quality of life
7. New trials in head and neck and renal cancers

 EORTC staff also spoke at three special sessions. Dr Madeline Pe, Head of the Quality-of-Life Department, presented highlights from the final recommendations of a global consortium dedicated to analysing patient-reported outcomes and Quality-of Life, during the ESMO-MCBS session ‘From Evidence to Reimbursement’.

Dr Denis Lacombe, EORTC CEO spoke about treatment optimisation from the perspective of a healthcare provider and trialist, exploring the value of clinical trials that further document the optimal use of therapeutic interventions.

Dr Lacombe also spoke on diversity, equity, and inclusion in clinical trials. Delivering clinical trials where the results can be safely applied to the majority of patients is a high societal priority. But conducting such trials addressing patient management and the utilisation of therapeutic interventions does not come without challenges, he said.

Please read the full summary of sessions, trials and research results on EORTC website.

You can also help support EORTC’s game-changing clinical research to unleash scientific breakthrough and transform cancer patients’ lives. Learn how to GET INVOLVED, or Make a Contribution Now.